European Heart Journal · 2008 · 265 citations · 32 references
MedicineCardiologyInternal MedicineClinical CardiologyElectrophysiologyRisk AssessmentCardiac ArrhythmiasCardiac Risk AssessmentCardiovascular RiskElectrocardiographyLeft Ventricular Function AssessmentMyocardial Infarction ComplicationsArrhythmic Risk AssessmentCardiovascular Risk StratificationDiagnostic Risk StratificationLeft Ventricular Ejection Fraction DeclineLife-threatening ArrhythmiasMyocardial Infarction Risk StratificationSudden Cardiac Death Risk AssessmentVentricular Ejection Fraction Assessment
AIMS: To determine whether risk stratification tests can predict serious arrhythmic events after acute myocardial infarction (AMI) in patients with reduced left ventricular ejection fraction (LVEF < or = 0.40). METHODS AND RESULTS: A total of 5869 consecutive patients were screened in 10 European centres, and 312 patients (age 65 +/- 11 years) with a mean LVEF of 31 +/- 6% were included in the study. Heart rate variability/turbulence, ambient arrhythmias, signal-averaged electrocardiogram (SAECG), T-wave alternans, and programmed electrical stimulation (PES) were performed 6 weeks after AMI. The primary endpoint was ECG-documented ventricular fibrillation or symptomatic sustained ventricular tachycardia (VT). To document these arrhythmic events, the patients received an implantable ECG loop-recorder. There were 25 primary endpoints (8.0%) during the follow-up of 2 years. The strongest predictors of primary endpoint were measures of heart rate variability, e.g. hazard ratio (HR) for reduced very-low frequency component (<5.7 ln ms(2)) adjusted for clinical variables was 7.0 (95% CI: 2.4-20.3, P < 0.001). Induction of sustained monomorphic VT during PES (adjusted HR = 4.8, 95% CI, 1.7-13.4, P = 0.003) also predicted the primary endpoint. CONCLUSION: Fatal or near-fatal arrhythmias can be predicted by many risk stratification methods, especially by heart rate variability, in patients with reduced LVEF after AMI.
32
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Gust H. Bardy, Kerry L. Lee, Daniel B. Mark et al. · New England Journal of Medicine · 2005 · 6.5K citations · Full text